Diagnostics of sepsis
Authors:
Miroslav Průcha 1; Martin Matějovič 2; Lenka Sedláčková 1
Authors‘ workplace:
Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha
1; Univerzita Karlova v Praze, Lékařská fakulta v Plzni, I. interní klinika FN
2
Published in:
Čas. Lék. čes. 2011; 150: 283-288
Category:
Review Article
Overview
Sepsis is a serious high mortality disease. As regards pathophysiology, it is a systemic inflammatory response to infection. Its timely diagnosis strongly influences mortality. The identification of biomarkers is used for diagnosing, monitoring, and prognosis in septic patients. The methods for their measurement cover a range of disciplines such as clinical biochemistry, haematology, immunology, and clinical microbiology. The most frequently used sepsis markers in routine clinical diagnostics are C-reactive protein and procalcitonin. The detection of selected cytokines, mediators, and surface markers in immunocompetent cells gives us further chance for improvement of this diagnostics. The methods of calculating gene expression represent a technology with a potential for the discovery of new biomarkers which would improve both diagnostics and therapy in the sense of personalized medicine.
Key words:
sepsis, diagnostics, biomarkers, tailored therapy, genomics, proteomics.
Sources
1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–874.
2. Levy MM, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003, 29: 530–538.
3. Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 341: 589–596.
4. Kumar A, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136: 1237–1248.
5. Schefold JC, et al. Interleukin–6 serum level assessment using a new qualitative point–of–care test in sepsis: A comparison with ELISA measurements. Clin Biochem 2008; 41: 893–898.
6. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010, 14: R15.
7. Becker Kl, et al. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008, 36: 941–952.
8. Morgenthaler NG, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res 2003, 35: 290–295.
9. Linscheid P, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003; 144: 5578–5584.
10. Simon L, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 15: 206–217.
11. Tang BM, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta–analysis. Lancet Infect Dis 2007; 7: 210–217.
12. Uzzan B, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med 2006, 34: 1996–2003.
13. Simon L, et al. Procalcitonin and C–reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med 2008, 9: 407–413.
14. Rey C, et al. Procalcitonin and C–reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med 2007; 33: 477–484.
15. Becker Kl, et al. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36: 941–952.
16. Dombusch HJ, et al. Procalcitonin – a marker of invasive fungi infection? Support Care Cancer 2005, 13: 343–346.
17. Porcel JM, et al. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 2009; 34: 1383–1389.
18. Ugajin M, et al. Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Euro Respir 2011; 37: 371–375.
19. Ugarte H, et al. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999; 27: 498–504.
20. Suprin E, et al. Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med 2000; 29: 1232–1238.
21. Zazula R, et al. Prokalcitonin nejen v iferenciální diagnostice zánětlivé odpovědi organismu. Anesteziologie a neodkladná péče 2002; 2: 86–91.
22. Molter GP, et al. Procalcitonin plasma concentrations and systemic inflammatory response following different types of surgery. Anaesthesist 2003; 52: 210–217.
23. Sponholz Ch, et al. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006; 10: R145.
24. Buhaescu I, et al. Serum procalcitonin in systemic autoimmune diseases – where are we now? Seminar Arthritis Rheum 2010; 40: 176–183.
25. Zazula R, et al. Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin. Crit Care 2007; 11: R131–R136.
26. Briel M, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168: 2000–2007.
27. Schuetz P, et al. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010; 8: 575–587.
28. Nobre V, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177: 498–505.
29. Kellum JA, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167: 1655–1663.
30. Wong HR, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008; 178: 276–282.
31. Calfee CS, et al. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med 2010; 38: 1436–1431.
32. Eichacker PQ, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197–1205.
33. Gogos CA, et al. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181: 176–180.
34. Kumar AT, et al. Cytokine profile in elderly patients with sepsis. Indian J Crit Care Med 2009; 13: 74–78.
35. Prucha M, et al. Significance of lipopolysaccharide-binding protein (an acute phase protein) in monitoring critically ill patients. Crit Care 2003; 7: R154R15–9.
36. Villar J, et al. Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One 2009; 4: e6818.
37. Sakr Y, et al. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med 2008; 36: 2014–2022.
38. Mierzchala M, et al. Quantitative indices of dynamics in concentrations of lipopolysaccharide-binding protein (LBP) as prognostic factors in severe sepsis/septic shock patients – comparison with CRP and procalcitonin. Clin Biochem 2011; 44: 357–363.
39. Bhandari V, et al. Hematologic profile of sepsis in neonates: neutrophil CD64 as a diagnostic marker. Pediatrics 2008; 121: 129–34.
40. Icardi M, et al. CD64 index provides simple and predictive testing for detection and monitoring of sepsis and bacterial infection in hospital patients. J Clin Microbiol 2009; 47: 3914–3619.
41. Sedláčková L, et al. Imunologické monitorování sepse průtokovou cytometrií – kvantitativní stanovení exprese HLA-DR na monocytech a CD64 na granulocytech. Epidemiologie, mikrobiologie, imunologie 2005; 54: 54–61.
42. Davis BH, et al. Neutrophil CD64 is an improved indicator of infection or sepsis in emergency department patients. Arch Pathol Lab Med 2006; 130: 654–661.
43. Livaditi O, et al. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine 2006; 36: 283–290.
44. Nuutila J, et al. The novel applications of the quantitative analysis of neutrophil cell surface FcgammaRI (CD64) to the diagnosis of infectious and inflammatory diseases. Curr Opin Infect Dis 2010; 23: 268–274.
45. Deitcher SR, Eisenberg PR. Elevated concentrations of cross–linked fibrin degradation products in plasma. An early marker of gram-negative bacteremia. Chest 1993; 103: 1107–1112.
46. Kinasewitz GT, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004, 8: R82–R90.
47. Iba T, et al. Predicting the severity of systemic inflammatory response syndrome (SIRS) – associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 2007; 63: 1093–1098.
48. Quick G, Eisenberg P. Bedside measurement of D-dimer in the identification of bacteremia in the emergency department. J Emerg Med 2000; 19: 217–223.
49. Goebel PJ, et al. A Pilot Study of the Performance Characteristics of the D-dimer in Presumed Sepsis. West J Emerg Med 2010; 11: 173–179.
50. Boldrick JC, et al. Stereotyped and specific gene expression programs in human innate immune responses to bakteria. PNAS 2002; 99: 972–977.
51. Prucha M, et al. Expression profiling: toward an application in sepsis diagnostics. Shock 2004; 22: 29–33.
52. Liu M, et al. Early days: genomics and human responses to infection. Curr Opin Microbiol 2006; 9: 312–319.
53. Calvano SE, et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 438: 1032–1037.
54. Pachot A, et al. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: A preliminary study. Immunology Letters 2006; 106: 63–71.
55. Wong HR, et al. Identification of pediatric septic shock subclasses based on genome–wide expression profiling. BMC Med 2009; 7: 34–39.
56. Wong HR, et al. Toward a clinically feasible gene expression-based subclassification strategy for septic shock: Proof of concept. Crit Care Med 2010; 38: 1955–1961.
57. Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 2011; 9: 71–79.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Early repolarisation syndrome and idiopathic ventricular fibrillation
- Temporal lobe epilepsy in adults and possibilities of neurosurgical treatment: the role of magnetic resonance
- Nonconvulsive status epilepticus
- Measurement of exhaled nitric oxide in the diagnosis of asthma